Targeted Therapy in Ovarian Cancer

Marcus Vetter; Alexandra Leary

doi:10.36000/hbT.OH.2021.08.033

Targeted Therapy in Ovarian Cancer

Marcus Vetter, Alexandra Leary

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

Résumé

Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding of OC biology has led to the development of several targeted therapies, including antiangiogenic agents and poly(ADP-ribose) polymerase (PARP) inhibitors. Cell cycle inhibitors and endocrine therapy such as selective estrogen receptor downregulators are currently under development. In this article, we provide an overview of the current and emerging targeted therapies in OC.

langue originale	Anglais
Pages (de - à)	50-58
Nombre de pages	9
journal	Healthbook TIMES Oncology Hematology
Volume	8
Numéro de publication	2
Les DOIs	https://doi.org/10.36000/hbT.OH.2021.08.033
état	Publié - 1 janv. 2021

Accès au document

10.36000/hbT.OH.2021.08.033

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{c33116b0b69e46fb86d0f5e59a0207a8,

title = "Targeted Therapy in Ovarian Cancer",

abstract = "Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding of OC biology has led to the development of several targeted therapies, including antiangiogenic agents and poly(ADP-ribose) polymerase (PARP) inhibitors. Cell cycle inhibitors and endocrine therapy such as selective estrogen receptor downregulators are currently under development. In this article, we provide an overview of the current and emerging targeted therapies in OC.",

keywords = "Ovarian cancer, PARP inhibitors, antiangiogenic agents, immunotherapy, targeted therapy",

author = "Marcus Vetter and Alexandra Leary",

year = "2021",

month = jan,

day = "1",

doi = "10.36000/hbT.OH.2021.08.033",

language = "English",

volume = "8",

pages = "50--58",

journal = "Healthbook TIMES Oncology Hematology",

issn = "2673-2092",

number = "2",

}

TY - JOUR

T1 - Targeted Therapy in Ovarian Cancer

AU - Vetter, Marcus

AU - Leary, Alexandra

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding of OC biology has led to the development of several targeted therapies, including antiangiogenic agents and poly(ADP-ribose) polymerase (PARP) inhibitors. Cell cycle inhibitors and endocrine therapy such as selective estrogen receptor downregulators are currently under development. In this article, we provide an overview of the current and emerging targeted therapies in OC.

AB - Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding of OC biology has led to the development of several targeted therapies, including antiangiogenic agents and poly(ADP-ribose) polymerase (PARP) inhibitors. Cell cycle inhibitors and endocrine therapy such as selective estrogen receptor downregulators are currently under development. In this article, we provide an overview of the current and emerging targeted therapies in OC.

KW - Ovarian cancer

KW - PARP inhibitors

KW - antiangiogenic agents

KW - immunotherapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85135059755&partnerID=8YFLogxK

U2 - 10.36000/hbT.OH.2021.08.033

DO - 10.36000/hbT.OH.2021.08.033

M3 - Review article

AN - SCOPUS:85135059755

SN - 2673-2092

VL - 8

SP - 50

EP - 58

JO - Healthbook TIMES Oncology Hematology

JF - Healthbook TIMES Oncology Hematology

IS - 2

ER -